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Background/Aims: Many patients are diagnosed with cryptogenic hepatocellular carcinoma (HCC) without metabolic 
syndrome (MS). We investigated the risk factors for cryptogenic HCC in patients with a low body mass index (BMI) or 
without MS. 
Methods: Thirty-six patients were diagnosed with cryptogenic HCC over a 10-year period at a tertiary research hospital. 
Data including BMI score and risk factors for MS were analyzed retrospectively. Patients with fewer than two risk factors 
for MS (n = 16) were compared with those with two or more risk factors (n = 20). Patients with high BMI (≥ 23 kg/m
2, n = 
20) were also compared with those with lower BMI (n = 16). 
Results: Patients with fewer than two risk factors for MS were significantly more likely to smoke and be hepatitis B surface 
antibodies (anti-HBs)-positive vs. patients with two or more risk factors. However, only smoking was statistically significant 
on multivariate analysis. Peaks of BMI were observed in two regions.
 Lower BMI was significantly associated with the 
presence of anti-HBs compared with high BMI, although this association was not statistically significant on multivariate 
analysis.
Conclusions: Smoking is a potential risk factor for cryptogenic HCC in patients without MS. Remote hepatitis B virus 
infection may be a risk factor for cryptogenic HCC in patients without MS or with a low BMI. 
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IntRoduCtIon
The incidence of hepatocellular carcinoma (HCC) 
is high in South Korea, which is an endemic area of 
hepatitis B virus (HBV) infection. Most forms of HCC are 
related to hepatitis B, hepatitis C, or alcohol intake [1,2]. 
Since the discovery of the hepatitis C virus (HCV), the 
incidence of cryptogenic HCC has decreased. However, in 
about 5-30% of HCC cases, the cause is unknown. Many 
retrospective studies investigating HCC in the setting of 
cryptogenic cirrhosis have supported the notion that non-
alcoholic fatty liver disease (NAFLD) is one of the causes 
of cryptogenic cirrhosis and can progress to HCC [3,4]. 
NAFLD reflects a constellation of metabolic syndrome 
components, including glucose intolerance, hypertension, 
dyslipidemia, and obesity. Cryptogenic HCC is diagnosed 
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when an extensive evaluation has excluded recognizable 
etiologies of chronic liver disease [5-7]. In South Korea, 
the incidence of cryptogenic HCC is increasing as cases of 
obesity and type II diabetes mellitus increase [1,8,9]. In 
Japan where obesity is rare, studies have reported that the 
features of cryptogenic HCC are related to components 
of metabolic syndrome such as obesity and glucose 
intolerance [10]. Thus, the association between cryptogenic 
HCC and metabolic syndromes is well known. 
However, in clinical practice, cryptogenic HCC may 
also occur in patients who are not obese and do not 
have metabolic syndrome. This study was conducted to 
investigate the risk factors for development of cryptogenic 
HCC in patients without metabolic syndrome or obesity. 
MethodS 
Patients and methods
Thirty-six patients diagnosed with cryptogenic HCC at 
a tertiary referral university hospital (Ilsan Paik Hospital, 
Inje University College of Medicine, Goyang, Korea) from 
January 2000 to December 2009 were included in the 
study. The diagnostic criteria for cryptogenic HCC were 
defined as HCC that is not related to hepatitis B, hepatitis 
C, or alcohol intake history. Autoimmune hepatitis, 
genetic liver disease, and Budd-Chiari syndrome were 
also excluded. The diagnosis of HCC was based on the 
criteria of the Korean Liver Cancer Study Group and the 
National Cancer Center [11]. The presence of hepatitis B 
surface antigen (HBsAg) was set as the criterion for HBV 
hepatitis, and the presence of HCV antibody was the 
criterion for HCV hepatitis. Those with alcohol-associated 
HCC, defined as male patients whose daily alcohol intake 
was 40 g or more for 10 years and female patients whose 
daily alcohol intake was 20 g or more for 10 years or more 
[12], were excluded from the study. The medical records of 
enrolled patients were retrospectively analyzed. 
A patient with glucose intolerance was defined as one 
whose glucose level was 110 mg/dL in at least two tests or 
a patient who was receiving diabetic medication or insulin 
treatment [13]. A patient with hypertension was defined as 
one who was taking an anti-hypertensive drug or whose 
blood pressure was > 140/90 mmHg [14]. A patient with 
dyslipidemia was defined as one whose triglyceride (TG) 
level was > 150 mg/dL, who was receiving treatment 
for TG, or whose high-density lipoprotein level was < 
40 mg/dL (male) or < 50 mg/dL (female) [14]. A smoker 
was defined as one who had a history of smoking of more 
than 20 pack-years [15]. In all patients, a biochemical 
test was performed and the Child-Pugh (CP) scores were 
calculated.
The body mass index (BMI) of the patients was 
calculated, and patients were divided into those with 
BMI ≥ 23 kg/m
2 or more and those with BMI < 23 kg/m
2, 
according to the criterion of 23 kg/m
2 BMI for overweight 
Asian males [16].
 The incidence of glucose intolerance, 
hypertension, dyslipidemia, smoking history, other cancer 
history, and hepatitis B surface antibodies (anti-HBs) 
positivity were compared.
The patients were also divided into two groups according 
to the number of risk factors they had for metabolic 
syndrome. These consisted of glucose intolerance, 
hypertension, dyslipidemia, and obesity, defined as BMI 
greater than 25 kg/m
2 [14]. The two groups were compared 
based on their smoking or non-smoking habit, anti-HBs 
status, other cancer history, and clinical data to identify 
the risk factors for HCC in these patients.
The study protocol was approved by the Institutional 
Review Board of Ilsan Paik Hospital, Inje University 
College of Medicine, Goyang, Korea.
Statistical analysis
SPSS version 11.0 (SPSS Inc., Chicago, IL, USA) was 
used to perform all analyses. The Pearson χ
2 test was used 
to compare the qualitative variables of those with a BMI of 
23 kg/m
2 or more and those with a BMI of less than 23 kg/
m
2, and of those who had two or more of the four factors 
constituting metabolic syndrome (glucose intolerance, 
hypertension, dyslipidemia, and a BMI ≥ 25 kg/m
2) with 
those who had fewer than two. Student’s t test was used to 
compare quantitative variables.
Variables that were significant by univariate analysis 
were tested by multivariate logistic regression to 
determine independent risk factors for cryptogenic HCC. 
Differences were considered significant at a two-sided p ≤ 
0.05.Song Hy, et al. Risk factors for cryptogenic HCC     49
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ReSuLtS
Baseline characteristics of the 36 cryptogenic hCC 
patients 
The 36 patients included 26 males and 10 females with a 
mean age of 72.4 ± 11.0 years (range, 48 to 88). The mean 
BMI was 24.1 ± 4.2 kg/m
2 (range, 15.8 to 32.4), and 20 
(55.6%) patients had a BMI ≥ 23 kg/m
2 (above the criterion 
for overweight). Detailed baseline clinical characteristics 
are shown in Table 1.
Fourteen (38.9%) patients had glucose intolerance, 21 
(58.3%) hypertension, 14 (38.9%) dyslipidemia, and 11 
were smokers. Eleven patients were anti-HBs-positive.
Comparison of clinical characteristics for crypto-
genic hCC according to the number of metabolic 
syndrome risk factors
The patients were divided into those with two or more of 
the four factors constituting metabolic syndrome (glucose 
intolerance, hypertension, dyslipidemia, and BMI ≥ 25 
[obesity]) and those with fewer than two. Although there 
was no significant difference in smoking habit, other 
cancer history, or level of alpha-fetoprotein between the 
two groups, the rate of anti-HBs positivity was significantly 
higher in the group without metabolic syndrome (58.3 
vs. 21%, respectively; p = 0.026). Additionally, smoking 
was significantly higher in the group without metabolic 
syndrome (50% vs. 15%, respectively; p = 0.034) (Table 
2). In a logistical regression analysis including anti-HBs 
and smoking as variables, anti-HBs positivity rate did not 
significantly differ between the two groups (odds ratio 
[OR], 0.29; 95% confidence interval [CI], 0.21 to 4.15; p = 
0.368), whereas smoking did differ significantly between 
the two groups (OR, 10.25; 95% CI, 1.49 to 70.43; p = 0.018) 
(Table 3).
Comparison of clinical characteristics between 
BMI ≥ 23 kg/m
2 and BMI < 23 kg/m
2 groups
The peak incidence of BMI was observed in two regions 
(18.5-22.9 kg/m
2 and 25-29.9 kg/m
2) (Fig. 1). Twenty 
(55.6%) patients had a BMI of 23 kg/m
2 or more, and 16 
(44.4%) patients had a BMI < 23 kg/m
2. There was no 
significant difference between the two groups in terms of 
glucose intolerance, hypertension, dyslipidemia, presence 
of another cancer, smoking habit, or CP score (Table 4). 
The number of anti-HBs-positive patients was significantly 
higher in the BMI < 23 kg/m
2 group on univariate 
analysis (69.2% vs. 11.1%, respectively, p = 0.003) (Table 
4). A binary logistic regression analysis that included 
age, hypertension, smoking habit, and anti-HBs found 
no statistically significant difference between groups in 
these variables, but smoking had an odds ratio of 6.42 for 
cryptogenic HCC in the low-BMI group, which suggests 
the possibility of a relationship (Table 5).
table 1. Baseline characteristics
Variables Cryptogenic hepatocellular carcinoma patients (n = 36)
Age, yr 72.42 ± 11.02
Male/Female 26/10
Body mass index ≥ 23 kg/m
2 20 (55.6)
Risk factors of metabolic syndrome
Glucose intolerance 14 (38.9)
Hypertension 21 (58.3)
Dyslipidemia 14 (38.9)
Smoking 11 (30.6)
Hepatitis B surface antibodies positive 11 (35.5)
Another cancer history 3 (8)
a
Alpha-fetoprotein, ng/dL 6,362.65 ± 16,006.6
Child-Pugh score 6.31 ± 1.5
Values are presented as mean ± SD or number (%).
aLung cancer, multiple myeloma, cholangiocarcinoma.50    The Korean Journal of Internal Medicine Vol. 27, No. 1, March 2012
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dISCuSSIon 
HCC is the most rapidly increasing cause of cancer death 
globally. It is estimated that half a million cases occur 
annually worldwide, making HCC the fifth most common 
malignancy in men and the ninth in women. Most HCC 
cases are fatal; thus, its incidence rate is very close to its 
mortality rate [17].
The well-known causes of HCC include HBV, HCV, 
and alcohol. The socioeconomic damage due to HCC 
is considerable in countries such as South Korea, 
where hepatitis B is endemic [18]. NAFLD, one of the 
pathophysiologies of metabolic syndromes, is another 
cause of HCC [5]. Thus, extensive studies on non-alcoholic 
steatohepatitis (NASH) and NAFLD for cryptogenic HCC 
are in progress [19,20].
NAFLD is one of the most common causes of abnormal 
liver enzyme levels in adults. It is marked by a generalized 
triglyceride deposition within the hepatic parenchyma 
that pathologically resembles the macrovesicular steatosis 
seen in alcoholic liver disease, but occurs in subjects 
without considerable alcohol consumption [21]. Several 
studies have examined the clinical progression from 
NAFLD to cirrhosis, HCC, and liver-related death [22,23].
 
As NAFLD may account for a substantial proportion of 
cases of cryptogenic cirrhosis, the occurrence of HCC 
among these patients was also examined. The prevalence 
of obesity and diabetes is significantly higher in patients 
with cryptogenic HCC compared with those with HCC 
associated with viral- or alcohol-related cirrhosis [24].
HCC also occurs, however, in patients whose condition 
is not related to NAFLD. It is meaningful that this study 
found a high rate of smoking and anti-HBs positivity in 
the patient group with BMIs < 23 kg/m
2, a level that is 
defined as a low BMI, and in those without metabolic 
syndrome. Smoking is also a cause of various cancers. 
Various carcinogens from smoking can cause cancer 
through direct contact with human organs or through 
immunological mechanisms or indirect metabolites that 
do not have direct contact with the organs [25].
 Although 
Table 2. Comparison of clinical characteristics according to number of MS risk factors
MS risk factors
< 2 (n = 16)
MS risk factors
≥ 2 (n = 20)
p value
Age, yr 73.88 ± 13.19 71.25 ± 9.12 0.504
Male/Female 12 (75)/4 (25) 14 (70)/6 (30) NS
Smoking 8 (50) 3 (15) 0.034
Anti-HBs positivity 7 (58.3) 4 (21) 0.026
Another cancer history 1 (6.3) 2 (10) NS
Child-Pugh score 6.63 ± 1.63 6.05 ± 1.43 0.276
Values are presented as mean ± SD or number (%).
MS, metabolic syndrome; NS, not significant; anti-HBs, hepatitis B surface antibodies.
table 3. Multivariate analysis of cryptogenic hepatocellular carcinoma without metabolic syndrome
Variables Odds ratios 95% Confidence interval p value
Hepatitis B surface antibodies   0.30 0.02-4.15 0.368
Smoking 10.25   1.49-70.43 0.018
14
12
10
8
6
4
2
0
 18.5 18.5-22.9 23-24.9 25-29.9 < 30
kg/m2
Figure 1. The distribution of body mass index in cryptogenic 
hepatocellular carcinoma patients. Peak body mass index inci-
dence was observed in two regions (18.5-22.9 kg/m
2 and 25-29.9 
kg/m
2).Song Hy, et al. Risk factors for cryptogenic HCC     51
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the effect of smoking on the liver remains controversial, 
recent studies showed that smoking is a risk factor for 
HCC and a synergic risk factor with alcohol and obesity 
[15,19]. Additionally, one study reported that smoking 
could decrease the treatment response to interferon in 
chronic hepatitis C [26]. Our data indicate that smoking 
may be an independent risk factor for HCC in patients with 
cryptogenic HCC who do not have metabolic syndrome 
(Tables 2 and 3). 
Studies have been conducted to identify the causes of 
cryptogenic HCC in patients who do not have hepatitis B 
or C and who are non-alcoholic. In particular, in East Asia, 
where the prevalence of hepatitis B is high, reports on the 
relationship between hepatitis B and cryptogenic HCC are 
constantly emerging. By investigating the status of viral 
markers in HBsAg-negative patients with HCC, studies 
have found that a history of or infection with occult 
hepatitis B could cause HCC [20,27,28].
 The integration of 
occult HBV into the human genome caused mutation of 
the p53 gene and induced hepatocarcinogenesis [29]. 
This study has several limitations. First, we did not 
determine whether the patients with HCC had a resolved 
past HBV infection or had been vaccinated. Additionally, 
as HBV DNA PCR was not performed, the HBV infection 
status could not be determined. 
This study is meaningful because we found that smoking 
is a risk factor for patients with HCC whose BMI is low 
and who do not have metabolic syndromes. Furthermore, 
this study suggests a relationship with past HBV infection. 
Further studies are required to ascertain whether past 
and/or occult HBV infection can integrate into the human 
genome in low-BMI patients to a greater degree than in 
patients with an above normal body weight.
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Table 4. Comparison of clinical characteristics between BMI ≥ 23 kg/m
2 and BMI < 23 kg/m
2
Characteristics
BMI < 23 kg/m
2
(n = 16)
BMI ≥ 23 kg/m
2
(n = 20)
p value
Age, yr 74.56 ± 10.53 70.70 ± 11.37 0.299
Male/Female 11 (68.7)/5 (31.3) 15 (75)/5 (25) 0.7
Risk factors of MS
Glucose intolerance 5 (31.3) 9 (45) 0.501
Hypertension 7 (43.8) 14 (70) 0.175
Dyslipidemia 8 (50) 6 (30) 0.307
Smoking 7 (43.8) 4 (20) 0.159
Anti-HBs positive 9 (69.2) 2 (11) 0.003
Another cancer history 1 (6.3) 2 (10) NS
Child-Pugh score 6.63 ± 1.2 6.05 ± 1.7 0.249
Values are presented as mean ± SD or number (%).
BMI, body mass index; MS, metabolic syndrome; anti-HBs, hepatitis B surface antibodies.
Table 5. Multivariate analysis of cryptogenic HCC in low BMI patients (BMI < 23 kg/m
2)
Variables Odds ratio 95% Confidence interval p value
Age 0.97 0.89-1.05 0.41
Hypertension 0.48  0.08-3.02 0.44
Anti-HBs 3.89    0.26-59.41   0.328
Smoking 6.42    0.64-64.58 0.11
HCC, hepatocellular carcinoma; BMI, body mass index; anti-HBs, hepatitis B surface antibodies.52    The Korean Journal of Internal Medicine Vol. 27, No. 1, March 2012
http://dx.doi.org/10.3904/kjim.2012.27.1.47 http://www.kjim.or.kr
RefeRenCeS
1.  Oh KC, Park SH, Park JC, et al. Is the prevalence of cryptogenic 
hepatocellular carcinoma increasing in Korea? Korean J Gas-
troenterol 2005;45:45-51.
2.  Nam SW, Jung JJ, Bae SH, et al. Clinical outcomes of delayed 
clearance of serum HBsAG in patients with chronic HBV infec-
tion. Korean J Intern Med 2007;22:73-76.
3.  Bugianesi E, Leone N, Vanni E, et al. Expanding the natural his-
tory of nonalcoholic steatohepatitis: from cryptogenic cirrhosis 
to hepatocellular carcinoma. Gastroenterology 2002;123:134-
140.
4.  Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, 
Lok AS. NAFLD may be a common underlying liver disease in 
patients with hepatocellular carcinoma in the United States. 
Hepatology 2002;36:1349-1354.
5.  Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver 
disease and hepatocellular carcinoma: a weighty connection. 
Hepatology 2010;51:1820-1832.
6.  Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular car-
cinoma: two growing epidemics with a potential link. Cancer 
2009;115:5651-5661.
7.  Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 
2009;13:631-647.
8.  Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas 
in patients with metabolic syndrome often develop without 
significant liver fibrosis: a pathological analysis. Hepatology 
2009;49:851-859.
9.  Park KS, Lee YS, Park HW, et al. Factors associated or related 
to with pathological severity of nonalcoholic fatty liver disease. 
Korean J Intern Med 2004;19:19-26.
10.  Kojima H, Sakurai S, Matsumura M, et al. Cryptogenic cirrhosis 
in the region where obesity is not prevalent. World J Gastroen-
terol 2006;12:2080-2085.
11.  Korean Liver Cancer Study Group; National Cancer Center, 
Korea. Practice guidelines for management of hepatocellular 
carcinoma 2009. Korean J Hepatol 2009;15:391-423.
12.  Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepa-
titis: summary of an AASLD Single Topic Conference. Hepatol-
ogy 2003;37:1202-1219.
13.  Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-al-
coholic fatty liver disease and its association with impaired glu-
cose metabolism in Japanese adults. Diabet Med 2005;22:1141-
1145.
14.  Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new 
world-wide definition: a Consensus Statement from the Inter-
national Diabetes Federation. Diabet Med 2006;23:469-480.
15.  Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok 
AS. Alcohol, tobacco and obesity are synergistic risk factors for 
hepatocellular carcinoma. J Hepatol 2005;42:218-224. 
16.  WHO Expert Consultation. Appropriate body-mass index for 
Asian populations and its implications for policy and interven-
tion strategies. Lancet 2004;363:157-163.
17.  El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. 
J Clin Gastroenterol 2002;35(5 Suppl 2):S72-S78.
18.  Lee HS, Lee JH, Choi MS, Kim CY. Comparison of the incidence 
of hepatocellular carcinoma in HBV-and HCV-associated liver 
cirrhosis: a prospective study. Korean J Hepatol 1996;2:21-28.
19.  Mori M, Hara M, Wada I, et al. Prospective study of hepatitis B 
and C viral infections, cigarette smoking, alcohol consumption, 
and other factors associated with hepatocellular carcinoma risk 
in Japan. Am J Epidemiol 2000;151:131-139.
20.  Shimada S, Aizawa R, Abe H, Suto S, Miyakawa Y, Aizawa Y. 
Analysis of risk factors for hepatocellular carcinoma that is 
negative for hepatitis B surface antigen (HBsAg). Intern Med 
2003;42:389-393.
21.  Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. 
Nonalcoholic steatohepatitis: an expanded clinical entity. Gas-
troenterology 1994;107:1103-1109.
22.  Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural 
history of nonalcoholic fatty liver: a follow-up study. Hepatology 
1995;22:1714-1719.
23.  Bhala N, Angulo P, van der Poorten D, et al. The natural his-
tory of nonalcoholic fatty liver disease with advanced fibrosis 
or cirrhosis: an international collaborative study. Hepatology 
2011;54:1208-1216.
24.  Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann 
Epidemiol 2007;17:863-869.
25.  El-Zayadi AR. Heavy smoking and liver. World J Gastroenterol 
2006;12:6098-6101.
26.  El-Zayadi A, Selim O, Hamdy H, et al. Impact of cigarette smok-
ing on response to interferon therapy in chronic hepatitis C 
Egyptian patients. World J Gastroenterol 2004;10:2963-2966.
27.  Higashi Y, Tada S, Miyase S, et al. Correlation of clinical charac-
teristics with detection of hepatitis B virus X gene in liver tissue 
in HBsAg-negative, and HCV-negative hepatocellular carci-
noma patients. Liver 2002;22:374-379.
28.  Yu MC, Yuan JM, Ross RK, Govindarajan S. Presence of anti-
bodies to the hepatitis B surface antigen is associated with an 
excess risk for hepatocellular carcinoma among non-Asians in 
Los Angeles County, California. Hepatology 1997;25:226-228.
29.  Tamori A, Nishiguchi S, Kubo S, et al. HBV DNA integration 
and HBV-transcript expression in non-B, non-C hepatocellular 
carcinoma in Japan. J Med Virol 2003;71:492-498.